Dr. Chamberlin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
71 Rogers Street
Epix Pharmaceuticals, Inc.
Cambridge, MA 02142Phone+1 617-250-6062
Education & Training
Mount Auburn HospitalInternship, Internal Medicine, 1999 - 2000
Boston University School of MedicineClass of 1999
Certifications & Licensure
MA State Medical License 2001 - 2025
Clinical Trials
- Phase 2 Study of Oral K201 for Prevention of AF Recurrence Start of enrollment: 2010 Apr 01
- Effects of Intravenous K201 on the Restoration of Sinus Rhythm in Subjects With Symptomatic Atrial Fibrillation Start of enrollment: 2011 Feb 01
- A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Refractory Angina Start of enrollment: 2023 Nov 01
Publications & Presentations
PubMed
- 12 citationsEffects of K201 on repolarization and arrhythmogenesis in anesthetized chronic atrioventricular block dogs susceptible to dofetilide-induced torsade de pointes.Thom R G Stams, Avram Oros, Roel van der Nagel, Jet D.M. Beekman, Paul Chamberlin
European Journal of Pharmacology. 2011-12-15 - 71 citationsHigh-Spatial-Resolution Multistation MR Angiography with Parallel Imaging and Blood Pool Contrast Agent: Initial ExperienceKonstantin Nikolaou, Harald Kramer, C. Grosse, Dirk A. Clevert, Olaf Dietrich
Radiology. 2006-12-01 - 40 citationsA summary of safety of gadofosveset (MS-325) at 0.03 mmol/kg body weight dose: Phase II and Phase III clinical trials data.Kohkan Shamsi, E. Kent Yucel, Paul Chamberlin
Investigative Radiology. 2006-11-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
